Ping-Chih Ho, Member at Ludwig Cancer Research Professor at University of Lausanne shared a post on LinkedIn:
“From 2016, everything started from Haiping Wang and we discovered how CD36 targeting may reprogram the TME. After co-funding Pilatus Biosciences with two friends (Raven Lin), my amazing formal trainees Yi-Ru Yu Laura Fernandez and many supporters, we finally enter to clinical phase with IND approval by FDA.
Stay tuned! PLT012 is coming to phase 1 trial in 2026!”
More posts featuring Ping-Chih Ho on OncoDaily.